BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, Ouatu A, Floria M. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).J Diabetes Res. 2020;2020:3920196. [PMID: 32832560 DOI: 10.1155/2020/3920196] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Wen X, Zhou X, Chen D, Cheng J, Ji L. Association between non-alcoholic fatty liver disease and diabetes-related microvascular complications: A retrospective cross-sectional study of hospitalized patients. Endocr Pract 2021:S1530-891X(21)00046-X. [PMID: 33601024 DOI: 10.1016/j.eprac.2021.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Hwangbo H, Kim MY, Ji SY, Kim SY, Lee H, Kim GY, Park C, Keum YS, Hong SH, Cheong J, Choi YH. Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro. Antioxidants (Basel) 2020;9:E1040. [PMID: 33114221 DOI: 10.3390/antiox9111040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Li T, Guan L, Wang X, Li X, Zhou C, Wang X, Liang W, Xiao R, Xi Y. Relationship Between Dietary Patterns and Chronic Diseases in Rural Population: Management Plays an Important Role in the Link. Front Nutr 2022;9:866400. [DOI: 10.3389/fnut.2022.866400] [Reference Citation Analysis]
4 Kim H, Lee DS, An TH, Park HJ, Kim WK, Bae KH, Oh KJ. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. Int J Mol Sci 2021;22:4495. [PMID: 33925827 DOI: 10.3390/ijms22094495] [Reference Citation Analysis]
5 Zarghamravanbakhsh P, Frenkel M, Poretsky L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metabol Open 2021;12:100149. [PMID: 34870138 DOI: 10.1016/j.metop.2021.100149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Xu X, Fang C, Wang Y, Lu F, Liu S. Integrating Network Pharmacology and Metabolomics to Elucidate the Mechanism of Action of Huang Qin Decoction for Treament of Diabetic Liver Injury. Front Pharmacol 2022;13:899043. [DOI: 10.3389/fphar.2022.899043] [Reference Citation Analysis]
7 Wu W, Xiang J, Chen X. Association Between Diabetes Mellitus and All-Cause and Cardiovascular Mortality Among Individuals With Ultrasound-Defined Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:773342. [PMID: 34992579 DOI: 10.3389/fendo.2021.773342] [Reference Citation Analysis]
8 Yabiku K. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. Front Endocrinol (Lausanne) 2021;12:768850. [PMID: 34950104 DOI: 10.3389/fendo.2021.768850] [Reference Citation Analysis]
9 Xu P, Wang S, Pang D. A Novel Identified Peptide Hormone "Metabolitin" Attenuates Lipid Absorption in the Small Intestine of Diabetic Mice with Nonalcoholic Fatty Liver Disease by Regulating Neurotensin and AMPK Signaling Pathway. Evid Based Complement Alternat Med 2021;2021:8386848. [PMID: 34621326 DOI: 10.1155/2021/8386848] [Reference Citation Analysis]
10 Zakaria Z, Othman ZA, Suleiman JB, Che Jalil NA, Ghazali WSW, Nna VU, Mohamed M. Hepatoprotective Effect of Bee Bread in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Rats: Impact on Oxidative Stress and Inflammation. Antioxidants (Basel) 2021;10:2031. [PMID: 34943134 DOI: 10.3390/antiox10122031] [Reference Citation Analysis]
11 Schattenberg JM, Anstee QM, Caussy C, Bugianesi E, Popovic B. Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. Expert Rev Gastroenterol Hepatol 2021;:1-14. [PMID: 34493137 DOI: 10.1080/17474124.2021.1974295] [Reference Citation Analysis]
12 Zang X, Sun M, Xian J, Yu H, Zhang X, Zhang C, Tan Q. Effects of acupuncture for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e23219. [PMID: 33217835 DOI: 10.1097/MD.0000000000023219] [Reference Citation Analysis]
13 He Q, Chen B, Wang G, Zhou D, Zeng H, Li X, Song Y, Yu X, Liang W, Chen H, Liu X, Wu Q, Wu L, Zhang L, Li H, Hu X, Zhou W. Co-Crystal of Rosiglitazone With Berberine Ameliorates Hyperglycemia and Insulin Resistance Through the PI3K/AKT/TXNIP Pathway In Vivo and In Vitro. Front Pharmacol 2022;13:842879. [PMID: 35571083 DOI: 10.3389/fphar.2022.842879] [Reference Citation Analysis]
14 Li H, Xu Q, Xu C, Hu Y, Yu X, Zhao K, Li M, Li M, Xu J, Kuang H. Bicyclol Regulates Hepatic Gluconeogenesis in Rats with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease by Inhibiting Inflammation. Front Pharmacol 2021;12:644129. [PMID: 34093184 DOI: 10.3389/fphar.2021.644129] [Reference Citation Analysis]
15 Lange NF, Graf V, Caussy C, Dufour JF. PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. Int J Mol Sci 2022;23:4305. [PMID: 35457120 DOI: 10.3390/ijms23084305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
16 Zobeiri M, Parvizi F, Kalhori MR, Majnooni MB, Farzaei MH, Abdollahi M. Targeting miRNA by Natural Products: A Novel Therapeutic Approach for Nonalcoholic Fatty Liver. Evid Based Complement Alternat Med 2021;2021:6641031. [PMID: 34426744 DOI: 10.1155/2021/6641031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Pastusiak K, Matuszewska E, Pietkiewicz D, Matysiak J, Bogdanski P. MALDI-TOF MS Characterisation of the Serum Proteomic Profile in Insulin-Resistant Normal-Weight Individuals. Nutrients 2021;13:3853. [PMID: 34836106 DOI: 10.3390/nu13113853] [Reference Citation Analysis]
18 Zhang PP, Choi HH, Ohliger MA. Detection of fatty liver using virtual non-contrast dual-energy CT. Abdom Radiol (NY) 2022;47:2046-56. [PMID: 35306577 DOI: 10.1007/s00261-022-03482-9] [Reference Citation Analysis]
19 Ren Z, Okyere SK, Xie L, Wen J, Wang J, Chen Z, Ni X, Deng J, Hu Y. Oral Administration of Bacillus toyonensis Strain SAU-20 Improves Insulin Resistance and Ameliorates Hepatic Steatosis in Type 2 Diabetic Mice. Front Immunol 2022;13:837237. [PMID: 35242140 DOI: 10.3389/fimmu.2022.837237] [Reference Citation Analysis]
20 Androutsakos T, Nasiri-Ansari N, Bakasis AD, Kyrou I, Efstathopoulos E, Randeva HS, Kassi E. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. Int J Mol Sci 2022;23:3107. [PMID: 35328527 DOI: 10.3390/ijms23063107] [Reference Citation Analysis]
21 Zakaria Z, Othman ZA, Bagi Suleiman J, Jalil NAC, Ghazali WSW, Mohamed M. Protective and Therapeutic Effects of Orlistat on Metabolic Syndrome and Oxidative Stress in High-Fat Diet-Induced Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Rats: Role on Nrf2 Activation. Vet Sci 2021;8:274. [PMID: 34822647 DOI: 10.3390/vetsci8110274] [Reference Citation Analysis]
22 Nascè A, Gariani K, Jornayvaz FR, Szanto I. NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook. Antioxidants (Basel) 2022;11:1131. [PMID: 35740032 DOI: 10.3390/antiox11061131] [Reference Citation Analysis]
23 Simino LADP, Fontana MF, de Fante T, Panzarin C, Ignacio-souza LM, Milanski M, Torsoni MA, Desai M, Ross MG, Torsoni AS. Hepatic Epigenetic Reprogramming After Liver Resection in Offspring Alleviates the Effects of Maternal Obesity. Front Cell Dev Biol 2022;10:830009. [DOI: 10.3389/fcell.2022.830009] [Reference Citation Analysis]
24 Wang J, Li T, Li M, Shi D, Tan X, Qiu F. Lycopene attenuates D-galactose-induced insulin signaling impairment by enhancing mitochondrial function and suppressing the oxidative stress/inflammatory response in mouse kidneys and livers. Food Funct 2022. [PMID: 35762205 DOI: 10.1039/d2fo00706a] [Reference Citation Analysis]
25 Choi A, Kim JH, Chung H, Ahn CW, Choi HJ, Kim Y, Nam JS, Nunemaker CS. The Effects of C. lacerata on Insulin Resistance in Type 2 Diabetes Patients. Journal of Diabetes Research 2022;2022:1-10. [DOI: 10.1155/2022/9537741] [Reference Citation Analysis]
26 Lee HB, Do MH, Jhun H, Ha SK, Song HS, Roh SW, Chung WH, Nam YD, Park HY. Amelioration of Hepatic Steatosis in Mice through Bacteroides uniformis CBA7346-Mediated Regulation of High-Fat Diet-Induced Insulin Resistance and Lipogenesis. Nutrients 2021;13:2989. [PMID: 34578867 DOI: 10.3390/nu13092989] [Reference Citation Analysis]
27 Won G, Choi SI, Kang CH, Kim GH. Lactiplantibacillus plantarum MG4296 and Lacticaseibacillus paracasei MG5012 Ameliorates Insulin Resistance in Palmitic Acid-Induced HepG2 Cells and High Fat Diet-Induced Mice. Microorganisms 2021;9:1139. [PMID: 34070604 DOI: 10.3390/microorganisms9061139] [Reference Citation Analysis]
28 Padda J, Khalid K, Khedr A, Tasnim F, Al-Ewaidat OA, Cooper AC, Jean-Charles G. Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. Cureus 2021;13:e17321. [PMID: 34557367 DOI: 10.7759/cureus.17321] [Reference Citation Analysis]
29 Khandelwal R, Dassanayake AS, Conjeevaram HS, Singh SP. Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist? World J Diabetes 2021; 12(9): 1479-1493 [PMID: 34630901 DOI: 10.4239/wjd.v12.i9.1479] [Reference Citation Analysis]
30 Chen H, Yang F, He X, Li T, Sun Y, Song J, Huang X, Guo W. Garcinia Biflavonoid 1 Improves Lipid Metabolism in HepG2 Cells via Regulating PPARα. Molecules 2022;27:1978. [DOI: 10.3390/molecules27061978] [Reference Citation Analysis]
31 Ilan Y. Improving Global Healthcare and Reducing Costs Using Second-Generation Artificial Intelligence-Based Digital Pills: A Market Disruptor. Int J Environ Res Public Health 2021;18:811. [PMID: 33477865 DOI: 10.3390/ijerph18020811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
32 Saydmohammed M, Jha A, Mahajan V, Gavlock D, Shun TY, DeBiasio R, Lefever D, Li X, Reese C, Kershaw EE, Yechoor V, Behari J, Soto-Gutierrez A, Vernetti L, Stern A, Gough A, Miedel MT, Lansing Taylor D. Quantifying the progression of non-alcoholic fatty liver disease in human biomimetic liver microphysiology systems with fluorescent protein biosensors. Exp Biol Med (Maywood) 2021;:15353702211009228. [PMID: 33957803 DOI: 10.1177/15353702211009228] [Reference Citation Analysis]